VANCOUVER, British Columbia, July 24, 2018 /PRNewswire/ --
Zecotek Photonics Inc. ("Zecotek" or the "Company")(TSX-V: ZMS) (Frankfurt: W1I) (OTCPK: ZMSPF), a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, is pleased to announce an internal restructuring to better align its intellectual property, photonics
"Due to the considerable interest in our technology and investment potential in our operating divisions, it was necessary to better align our photonics technology, intellectual property and associated business functions across our three operating divisions," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. "We have recently completed two divisional equity financings in Zecotek Imaging Systems (Singapore) and Zecotek Imaging China, from the same strategic group, which puts us in a strong financial position moving forward. Our LFS Crystal Production Facility in Shanghai is coming online and has produced its first crystal boules. The company is building strength and gaining control of the production of its technologies."
All patents, with the exception those patents covering LFS scintillation crystals, have been transferred to Zecotek Optronics Systems. Patents pertaining to the LFS scintillation crystals will remain in Zecotek Imaging Systems (Singapore).
Zecotek Display Systems has been renamed Zecotek Autotronics Systems to focus on developing components for autonomous and semi-autonomous vehicles and industrial machinery.
Zecotek Optronics Systems has granted exclusive license rights to:
In return for the exclusive rights to intellectual property, Zecotek Optronics Systems will generate revenue through the collection of licensing fees from Zecotek Imaging Systems (Singapore) and Zecotek Autotronics Systems.
Zecotek Imaging China, a subsidiary of Zecotek Imaging Systems (Singapore), is commercializing patented LFS scintillation crystals through its new crystal production facility in Shanghai, China. Zecotek Imaging China is poised to become a leader in large-scale production, cutting and polishing of scintillation crystals grown by the Czochralski method in China. Using a proprietary manufacturing process, very large-diameter boules with uniform properties and without cracks are produced resulting in high element output with lower unit costs.
Zecotek's patented (US patent No. 7,132,060) LFS scintillation crystals are known for their superiority in performance. Zecotek's LFS crystals are known for their high light yields and ultra-fast decay times which allow for faster and higher-resolution operation of medical and industrial imaging devices including PET medical scanners. The Company's line of LFS crystals also cover a wide range of emission wavelengths which can be tailored to match the spectral sensitivity of various photo detectors including the Company's own solid-state MAPD photo detector arrays.
Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I; OTCPK: ZMSPF) is a photonics technology company developing high-performance scintillation crystals, solid-state photo detectors, 3D displays and related technologies for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek has three operating divisions: Zecotek Imaging Systems, Zecotek Optronics Systems, and Zecotek Autotronics with labs located in Canada, Korea, Russia, Singapore and U.S.A. It is commercializing over 55 patented and patent pending novel photonic technologies directly and through strategic alliances with the Shanghai EBO Optoelectronics Technology Company (China), Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit http://www.zecotek.com and follow @zecotek on Twitter.
This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future, please visit the corporate website at http://www.zecotek.com.
For Additional Information Please Contact: Zecotek Photonics Inc. Michael Minder T: +1(604)783-8291 email@example.com
SOURCE Zecotek Photonics Inc.
Subscribe to our Free Newsletters!
Oxidative stress is a form of injury to body tissues due to increase in free radicals. If the ...
Graviola's health benefits range from curing headaches to fighting cancer. Read on to know more ...
Gene therapy is a specialized procedure where genetic material is introduced into the cells of a ...View All